Quantitative evaluation of selective Janus kinase inhibitors for atopic dermatitis
AIM To quantitative evaluate of selective Janus kinase inhibitors in treatment of atopic dermatitis,and provide scientific basis for drug selection and clinical rational drug use.METHODS According to the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition),a comprehensive evaluation of upadacitinib and abrocitinib was conducted from five aspects of pharmaceutical characteristics,efficacy,safety,economy,and other attributes,and scores were assigned.RESULTS The total scores of upadacitinib and abrocitinib were 80.5 and 80.2 respectively.Upadacitinib and abrocitinib had definite therapeutic effects in terms of itching relief,and skin lesion clearance.But when combined with topical corticosteroids and other drugs,the improvement in efficacy of abrocitinib was better than that of upadacitinib.Upadacitinib had a wider range of applicability compared to abrocitinib,but the incidence of adverse reactions in the blood system of abrocitinib was lower than that of upadacitinib.Upadacitinib and abrocitinib were recommended for admission.CONCLUSION Abrocitinib is suitable for patients who seek quick results and build confidence,as well as those who need to flexibly adjust treatment plans based on their condition.Upadacitinib is preferred for adolescents over 12 years old,patients with severe renal insufficiency,or concomitant diseases such as rheumatoid arthritis and ulcerative colitis.
NETL
NSTL
万方数据
